Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin - sprookjes - yvandenbroek - TriplyDB

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

http://www.wikidata.org/entity/Q24642412

about

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia Activation of pancreatic-duct-derived progenitor cells during pancreas regeneration in adult rats Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.Sitagliptin-induced pancreatitis - a longer road than expected Molecular and cellular mechanisms of pancreatic injury.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop.Incretin-based therapies in prediabetes: Current evidence and future perspectives Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Severe acute pancreatitis in pregnancy The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.Skp2 is required for incretin hormone-mediated β-cell proliferation The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.The double trouble of metabolic diseases: the diabetes-cancer link.The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.

P2860

Q24568148-817561DC-E542-4FB4-94E2-2043E6683D16 Q24598747-47CFFC96-19C4-4948-B4AE-77329E7B0FDC Q26749089-E47022E6-98E6-4F59-849F-49F5D23D0D57 Q26765609-AA560293-87A4-4315-B724-31DD09A8171A Q26827183-9F340256-5A04-4844-AD39-823F86EB22AD Q27339590-2769C1B3-F35E-4C37-BDEE-94EA594377DB Q28286911-D586D7F8-A651-4208-99DA-BA8C3E93C392 Q28395600-E53273EE-4590-4B9E-A8B9-7521A81CA673 Q30410721-358B7F73-8D69-4734-8180-8AEC685779AE Q30513617-642D07D2-A6FB-4CE9-9180-F96687FDF3BA Q33562131-6321A691-AE3F-44FF-9ED8-6D1BD3A8AF19 Q33602360-08868B44-E66D-4CFD-98D5-6DEA57FC791F Q34003019-13616208-41B4-4745-9645-C90E29AF831B Q34041974-E3AFF885-5DEF-4FB5-8588-2F9F958380D9 Q34043378-DB7861AF-252C-48D7-B829-B3CC6151B75E Q34237350-663273A1-EACE-4537-A3B2-B28E6E0B072D Q34273302-2ED0C57A-97CD-4612-AF4D-D82C5D7522E7 Q34278297-BF4AD4CE-1AD9-4673-934D-C4433BC87310 Q34286707-A0277FF8-209D-4713-B2B4-CCCBA27E827C Q34501606-755607B4-65C1-4AF5-857E-FA9E31EEF661 Q34627077-37635B31-3A38-46B3-9F3C-CFE0BFDD152D Q34656874-7F464F76-FE30-43B0-9571-09EDDD84687F Q34699191-1DDB7A71-8D11-4040-A97F-E1EAC9F37F63 Q34780873-50E309A7-DCE2-42CD-9D6B-0CB870322235 Q34986823-741932B1-4582-471D-82CD-3619CBFC58EB Q35022184-6DDE7F5B-128D-4AB7-A9B3-BA4C2BE0AD28 Q35026483-C8A6B435-6EA8-4BF0-9631-118D271AE8E7 Q35055522-2CDC853C-28E1-4A16-AE41-203E994B4DB6 Q35260937-19837BD3-682F-4194-BEDE-22AC99E7FF4E Q35595675-999BEF0A-3672-4D23-93D6-AED6F962602B Q35902899-EFAE8705-75FE-47FD-8919-7F2F7B6CD94E Q36058422-3E4E998A-43A1-4962-B8EF-714C0197F02A Q36064999-B8F9237C-9972-44D6-B74A-18921A1732D7 Q36158841-C3FE0D59-CC4A-419B-8E51-1866073CEBA1 Q36420499-EE92AFFD-0660-4396-A87D-1F44027C5E2F Q36456052-8736C174-1644-4AD8-AB5F-48DB52B7EAA8 Q36523427-1E9ECD5F-5F7B-40AD-8486-6F892DA53F13 Q36665328-D4702FB9-35AE-4851-B0EF-912E82C6B691 Q36942123-32BC661B-60AD-4D31-B775-EFA82AA65FC0 Q37033531-7E80DC05-38E6-4992-B331-AC53B5753A7F

P2860

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

http://www.wikidata.org/entity/Q24642412

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Beneficial endocrine but adver ...... s: interactions with metformin

@ast

Beneficial endocrine but adver ...... s: interactions with metformin

@en

Beneficial endocrine but adver ...... s: interactions with metformin

@nl

type

label

Beneficial endocrine but adver ...... s: interactions with metformin

@ast

Beneficial endocrine but adver ...... s: interactions with metformin

@en

Beneficial endocrine but adver ...... s: interactions with metformin

@nl

prefLabel

Beneficial endocrine but adver ...... s: interactions with metformin

@ast

Beneficial endocrine but adver ...... s: interactions with metformin

@en

Beneficial endocrine but adver ...... s: interactions with metformin

@nl

P1433

Q24642412-2B358DF8-DAF3-42C9-A182-EAB11801DF6A

P1476

Q24642412-54398E0B-22AF-440E-B99C-2FB5EC109A49

P2093

Q24642412-22656E6D-C79F-4D78-A508-12024ACEC36B

Q24642412-4B57DC79-0F68-4B18-8B50-4B623128A5A3

Q24642412-734A8634-EBF6-402A-A82C-4FEDABAEB922

Q24642412-839EC578-4953-4551-9CD4-AEDA6077D85A

Q24642412-874D0751-453D-490D-A367-0CA9887BC04E

Q24642412-ABC9583E-E54F-47F2-8927-9063C8DB4FBD

Q24642412-CDAB86DC-BDE2-4711-847B-37BDB10313BF

Q24642412-E17BE145-E39B-4FB7-8147-5224EA6994A6

P2860

Q24642412-086CE028-99A3-47EF-945B-1A527F60DA18

Q24642412-0A01DB7E-E883-494F-B817-CA56B21BC624

Q24642412-10F90CB1-BEBA-4549-882F-A19712A5702B

Q24642412-157D2769-8355-4CEB-B93E-CF0D74273579

Q24642412-229E9CB6-1B10-4035-8915-FB38B150260C

Q24642412-22B70AA5-F4A5-479D-9450-9953F099EB1B

Q24642412-24947A79-C19C-4F2D-940A-96410055F104

Q24642412-2926BC29-F3EC-405A-A4F6-42F7AEACDB89

Q24642412-2B8F4867-8199-46DC-A783-FD2D4EA0F27E

Q24642412-2E6FC233-3E46-4B0E-B879-AA7D3AB95875

P304

Q24642412-0E036085-C434-4918-8B68-07CD37571720

P31

Q24642412-CDBBB711-731A-4966-B66E-1B9E29B87732

P3181

Q24642412-47F27297-A6D8-482F-BAC1-662EB3848952

P356

Q24642412-954714B0-169E-4C58-B287-11CF9E9E677D

P407

Q24642412-C8F7F1DE-7DA3-46F5-85E4-D5E8C94591A3

P433

Q24642412-0220E981-BEBC-427F-AEB3-1384873FD427

P478

Q24642412-E5C5D0DE-A020-4B65-BBEB-A623955FD061

P577

Q24642412-17ED3646-E618-4C61-B271-D1C458F82368

P5875

Q24642412-8C7E798B-20B9-4291-9FF6-F844B25172D4

P698

Q24642412-B67FC03C-0F4A-4D5D-A336-97B21538938C

P921

Q24642412-9BD6289F-DB4E-4EA4-95DF-12330550D2E5

Q24642412-E169CA33-F1F0-41CB-8D56-73E8C169B616

P932

Q24642412-712700F5-4EC5-4E70-A164-DBB1BF3E8F5B

P3181

P356

P1433

P1476

Beneficial endocrine but adver ...... s: interactions with metformin

@en

P2093

Aleksey V Matveyenko

http://www.w3.org/2001/XMLSchema#string

Alexandra E Butler

http://www.w3.org/2001/XMLSchema#string

Artemis Moshtaghian

http://www.w3.org/2001/XMLSchema#string

Heather I Cox

http://www.w3.org/2001/XMLSchema#string

Peter C Butler

http://www.w3.org/2001/XMLSchema#string

Ryan Galasso

http://www.w3.org/2001/XMLSchema#string

Sarah Dry

http://www.w3.org/2001/XMLSchema#string

Tatyana Gurlo

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

Metformin and reduced risk of cancer in diabetic patients

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus

P304

1604-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3166009

http://www.w3.org/2001/XMLSchema#string

P356

10.2337/DB09-0058

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24378716

http://www.w3.org/2001/XMLSchema#string

P698

19403868

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2699878

http://www.w3.org/2001/XMLSchema#string